Entera Bio Analyst Ratings
Entera Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 1414.92% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 09/11/2023 | 1414.92% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/08/2023 | 1414.92% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 04/04/2023 | 1414.92% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/28/2023 | 1414.92% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 09/06/2022 | 1414.92% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/19/2022 | 657.46% | B. Riley Securities | $6 → $5 | Maintains | Buy |
| 06/16/2021 | 1263.43% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 03/22/2021 | 1717.9% | Aegis Capital | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/13/2023 | 1414.92% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 09/11/2023 | 1414.92% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 05/08/2023 | 1414.92% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 04/04/2023 | 1414.92% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 03/28/2023 | 1414.92% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 09/06/2022 | 1414.92% | HC Wainwright公司 | →$10 | 開始承保 | →購買 |
| 07/19/2022 | 657.46% | B.萊利證券 | $6→$5 | 維護 | 買 |
| 06/16/2021 | 1263.43% | B.萊利證券 | →$9 | 開始承保 | →購買 |
| 03/22/2021 | 1717.9% | 宙斯盾資本 | →$12 | 開始承保 | →購買 |
What is the target price for Entera Bio (ENTX)?
Entera Bio的目標價是多少？
The latest price target for Entera Bio (NASDAQ: ENTX) was reported by HC Wainwright & Co. on September 13, 2023. The analyst firm set a price target for $10.00 expecting ENTX to rise to within 12 months (a possible 1414.92% upside). 5 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年9月13日報道了Entera Bio(納斯達克代碼：ENTX)的最新目標價。這家分析公司將目標價定為10美元，預計ENTX將在12個月內上漲至(可能上漲1414.92%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Entera Bio (ENTX)?
分析師對Entera Bio的最新評級是多少？
The latest analyst rating for Entera Bio (NASDAQ: ENTX) was provided by HC Wainwright & Co., and Entera Bio reiterated their buy rating.
納斯達克(股票代碼：ENTX)的最新分析師評級由HC Wainwright&Co.提供，Entera Bio重申其買入評級。
When is the next analyst rating going to be posted or updated for Entera Bio (ENTX)?
Entera Bio(ENTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entera Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entera Bio was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Entera Bio的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Entera Bio的上一次評級是在2023年9月13日提交的，所以你應該預計下一次評級將在2024年9月13日左右的某個時候提供。
Is the Analyst Rating Entera Bio (ENTX) correct?
分析師對Entera Bio的評級正確嗎？
While ratings are subjective and will change, the latest Entera Bio (ENTX) rating was a reiterated with a price target of $0.00 to $10.00. The current price Entera Bio (ENTX) is trading at is $0.66, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Entera Bio(ENTX)評級被重申，目標價在0.00美元至10.00美元之間。Entera Bio目前的交易價格為0.66美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。